Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia - Results of a phase i dose-escalation study

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 7, 2015, Pages 443-449

  Dipersio, John F ^a   Erba, Harry P ^b   Larson, Richard A ^c   Luger, Selina M ^d   Tallman, Martin S ^e   Brill, Jeffrey M ^f   Vuagniaux, Gregoire ^g   Rouits, Elisabeth ^g   Sorensen, J Mel ^f   Zanna, Claudio ^g  

^a Washington University in St Louis School of Medicine   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f Ascenta Therapeutics   (United States)

^g DEBIOPHARM SA   (Switzerland)

Author keywords

cIAP1; Interleukin; Pharmacokinetics; TNF; Treatment resistance

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILEUKEMIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; DEBIO 1143; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; STEM CELL FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AZOCINE DERIVATIVE; BENZHYDRYL DERIVATIVE; CYTOKINE; INHIBITOR OF APOPTOSIS PROTEIN; N-BENZHYDRYL-5-(2-(METHYLAMINO)PROPANAMIDO)-3-(3-METHYLBUTANOYL)-6-OXODECAHYDROPYRROLO(1,2-A)(1,5)DIAZOCINE-8-CARBOXAMIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; BONE MARROW; CANCER RISK; CLINICAL ARTICLE; COHORT ANALYSIS; CONVALESCENCE; DECREASED APPETITE; DIARRHEA; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TOLERABILITY; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEART DISEASE; HUMAN; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPOKALEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OPEN STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; QT PROLONGATION; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZOCINES; BENZHYDRYL COMPOUNDS; CYTARABINE; CYTOKINES; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED;

EID: 84937520417     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2015.02.020     Document Type: Article

References (38)

1. J.C. Reed Apoptosis-targeted therapies for cancer Cancer Cell 3 2003 17 22
2. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
3. E.C. LaCasse, D.J. Mahoney, H.H. Cheung, and et al. IAP-targeted therapies for cancer Oncogene 27 2008 6252 6275
4. A.M. Hunter, E.C. LaCasse, and R.G. Korneluk The inhibitors of apoptosis (IAPs) as cancer targets Apoptosis 12 2007 1543 1568
5. S. Fulda Inhibitor of apoptosis proteins as targets for anticancer therapy Expert Rev Anticancer Ther 7 2007 1255 1264
6. M. Gyrd-Hansen, and P. Meier IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer Nat Rev Cancer 10 2010 561 574
7. E. Varfolomeev, T. Goncharov, A.V. Fedorova, and et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation J Biol Chem 283 2008 24295 24299
8. S. Mehrotra, L.R. Languino, C.M. Raskett, and et al. IAP regulation of metastasis Cancer Cell 17 2010 53 64
9. S.L. Petersen, L. Wang, A. Yalcin-Chin, and et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to SMAC-mimetic-induced apoptosis Cancer Cell 12 2007 445 456
10. T.J. Shaw, E.C. Lacasse, J.P. Durkin, and et al. Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo Int J Cancer 122 2008 1430 1434
11. A.D. Schimmer, K. Welsh, C. Pinilla, and et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity Cancer Cell 5 2004 25 35
12. B.Z. Carter, M. Milella, T. Tsao, and et al. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia Leukemia 17 2003 2081 2089
13. British Committee for Standards in Haematology, D.W. Milligan, D. Grimwade, and et al. Guidelines on the management of acute myeloid leukaemia in adults Br J Haematol 135 2006 450 474
14. A.H. Goldstone, A.K. Burnett, K. Wheatley, and et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial Blood 98 2001 1302 1311
15. J.F. Yamamoto, and M.T. Goodman Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002 Cancer Causes Control 19 2008 379 390
16. F.R. Appelbaum, H. Gundacker, D.R. Head, and et al. Age and acute myeloid leukemia Blood 107 2006 3481 3485
17. J.W. Yates, H.J. Wallace Jr., R.R. Ellison, and et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia Cancer Chemother Rep 57 1973 485 488
18. H. Kantarjian, F. Ravandi, S. O'Brien, and et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia Blood 116 2010 4422 4429
19. T. Buchner, W. Hiddemann, B. Wormann, and et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group Blood 93 1999 4116 4124
20. E. Estey Acute myeloid leukemia and myelodysplastic syndromes in older patients J Clin Oncol 25 2007 1908 1915
21. E.J. Feldman, D.S. Alberts, Z. Arlin, and et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia J Clin Oncol 11 1993 2002 2009
22. I.M. Hann, R.F. Stevens, A.H. Goldstone, and et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council Blood 89 1997 2311 2318
23. D. Russo, M. Malagola, A. de Vivo, and et al. Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients Br J Haematol 131 2005 172 179
24. A.D. Schimmer, E.H. Estey, G. Borthakur, and et al. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia J Clin Oncol 27 2009 4741 4746
25. J.W. Vardiman, J. Thiele, D.A. Arber, and et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 2009 937 951
26. D. Grimwade, R.K. Hills, A.V. Moorman, and et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials Blood 116 2010 354 365
27. L. Dubrez, J. Berthelet, and V. Glorian IAP proteins as targets for drug development in oncology Onco Targets Ther 9 2013 1285 1304
28. S. Fulda Molecular pathways: targeting inhibitor of apoptosis proteins in cancer-from molecular mechanism to therapeutic application Clin Cancer Res 20 2014 289 295
29. Hurwitz HI, Smith DC, Pitot HC, et al. Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study. Cancer Chemother Pharmacol Epub 2015 Feb 27.
30. R.I. Erickson, J. Tarrant, G. Cain, and et al. Toxicity profile of small-molecule IAP antagonist GDC-0152 is linked to TNF-alpha pharmacology Toxicol Sci 131 2013 247 258
31. Y. Akazawa, M.E. Guicciardi, S.C. Cazanave, and et al. Degradation of cIAPs contributes to hepatocyte lipoapoptosis Am J Physiol Gastrointest Liver Physiol 305 2013 G611 G619
32. P. Niscola, C. Romani, L. Cupelli, and et al. Mucositis in patients with hematologic malignancies: an overview Haematologica 92 2007 222 231
33. A. Rudiger, and M. Singer Mechanisms of sepsis-induced cardiac dysfunction Crit Care Med 35 2007 1599 1608
34. M.M. Parker, J.H. Shelhamer, S.L. Bacharach, and et al. Profound but reversible myocardial depression in patients with septic shock Ann Intern Med 100 1984 483 490
35. J.D. Young The heart and circulation in severe sepsis Br J Anaesth 93 2004 114 120
36. S.H. Wan, D.H. Huffman, D.L. Azarnoff, and et al. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans Cancer Res 34 1974 392 397
37. J. Holowiecki, S. Grosicki, T. Robak, and et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia: multicenter, phase III study Leukemia 18 2004 989 997
38. A. Tefferi, and L. Letendre Going beyond 7 + 3 regimens in the treatment of adult acute myeloid leukemia J Clin Oncol 30 2012 2425 2428